• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

Mumbai, Aug. 10

Ethypharm India has inked a deal for out-licensing five new products in different therapeutic segments with UAE-based Globalpharma. The deal comes in quick succession after a similar deal that Ethypharm signed with Globalpharma for development and supply of Cetirizine 10 mg Oro-dispersible tablets last year.

Ehtypharm is 100 per cent subsidiary of leading French multinational drug delivery company Ethypharm S.A. The products that form the deal include Paracetamol 500mg Flashtab (Analgesic Antipyretic); Ciprofloxacin Sustained Release 1000mg (Antibiotic); Metformin Sustained Release 1000mg (Antidiabetic); Gliclazide Sustained Release 30mg (Antidiabetic); and Pseudoephedrine Sustained Release 120mg and Cetirizine 5 mg in combination (Antiallergic).

Under the terms of the agreement, Ethypharm India will be responsible for the development and supply of the products and Globalpharma will be responsible for marketing and distribution in West Asia and Gulf countries markets. Globalpharma Co LLC, is a joint venture company in UAE, and a subsidiary of Dubai Investment PJC.

More Stories on : Alliances & Joint Ventures | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
ONGC declares force majeure on naphtha

Copyright © 2006, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line